07/24/2008		IsoRay Receives No List of Observations (form FDA 483) in FDA Inspection
06/12/2008		IsoRay Conducts Second Proxcelan Cs-131 Workshop at Chicago Prostate Cancer Center in 2008
06/03/2008		IsoRay Inc. Announces Authorization of Stock Repurchase Plan
05/13/2008		IsoRay, Inc. Reports Third Quarter Results
05/06/2008		IsoRay Inc. Announces Third Quarter Fiscal 2008 Earnings Release Date and Conference Call
02/27/2008		IsoRay Appoints New Chairman and Interim CEO and Announces Management Changes Upon Incumbent Resignation
02/11/2008		IsoRay Inc. Reports Second Quarter Results
02/07/2008		IsoRay Conducts Proxcelan Cs-131 Workshop at Chicago Prostate Cancer Center
02/06/2008		IsoRay announces date of annual shareholders meeting
02/04/2008		IsoRay Inc. Announces Second Quarter Fiscal 2008 Earnings Release Date and Conference Call
01/23/2008		IsoRay Medical Announces New Russian Agreement
01/15/2008		IsoRay Announces Director Not Standing for Re-Election
12/13/2007		IsoRay's Cesium-131 Medical Isotope used in milestone procedure treating eye cancers at Tufts-New England Medical Center
11/27/2007		IsoRay Inc Selects Allen & Caron For Investor Relations and Corporate Communications
11/08/2007		IsoRay, Inc. First Quarter Fiscal Year 2008 Results
11/01/2007		New studies unveiled at ASTRO’s 49th annual meeting of radiation oncology specialists support the effectiveness of IsoRay Medical’s Proxcelan™ for the treatment of prostate cancer
10/29/2007		IsoRay Inc. announces first quarter fiscal 2008 earnings release date and conference call
10/24/2007		IsoRay Medical spotlights launch of Proxcelan™ branding at ASTRO; leading physicians to release latest scientific findings focusing on effectiveness of Cesium-131 in treating prostate cancer
10/01/2007		IsoRay Announces Global Strategic Alliance with IBt s.a.
09/28/2007		IsoRay Inc. Reports Fiscal Year End 2007 Results
08/29/2007		IsoRay Medical, Inc. set to transfer production of Proxcelan™ (Cesium-131) brachytherapy seeds to new expanded facilities in Richland
08/09/2007		Leading medical centers join growing number of locations offering IsoRay’s prostate cancer treatment Proxcelan™ brachytherapy seeds (Cesium-131)
08/07/2007		Scientific findings on Proxcelan™ brachytherapy seeds (Cesium-131) presented at 26th Annual AAPM meeting for innovative research and development
07/20/2007		IsoRay Medical, Inc. introduces branding of Cesium-131 as Proxcelan™ for use in prostate cancer brachytherapy
07/20/2007		Scientific abstracts on the newest isotope used in brachytherapy for prostate cancer--IsoRay Medical’s Proxcelan™ with Cesium-131--presented at the American Association of Physicists in Medicine (AAPM) annual conference, July 22-26
05/09/2007		IsoRay Medical, Inc. and the Applied Process Engineering Laboratory sign lease for new Cesium-131 production facility in Richland
04/30/2007		New study shows that Cesium-131 from IsoRay Medical™ is an effective, well-tolerated brachytherapy treatment for prostate cancer with fewer side effects than other medical isotopes
04/30/2007		Cesium-131 from IsoRay Medical™, Inc. established as a front line treatment for early stage prostate cancer treatment in a recent clinical trial
04/19/2007		04/16/2007 IsoRay, Inc. to be listed on the American Stock Exchange; Shares to Trade Under the Symbol ISR
04/16/2007		IsoRay, Inc. to be listed on the American Stock Exchange; Shares to Trade Under the Symbol ISR
04/05/2007		IsoRay Medical continues to expand market adoption of Cesium-131 during third quarter 2007
03/28/2007		ISORAY, Inc. ANNOUNCES COMPLETION OF WARRANT CALL
03/23/2007		ISORAY, Inc. ANNOUNCES MAJOR PUBLIC FINANCING
02/21/2007		IsoRay Announces Second Quarter 2007 Results and Call of Warrants
02/07/2007		Clinical data on IsoRay Medical’s Cesium-131 to be presented at the 28th American Brachytherapy Society Annual Meeting
02/02/2007		IsoRay, Inc. Adopts Share Rights Plan, Adopts By-Law Amendments
01/17/2007		IsoRay Medical™ significantly increases site licensing pipeline of Cesium-131 from first to second fiscal quarter 2007
12/04/2006		IsoRay Announces Effectiveness of Registration Statement Relating to 9,064,890 Shares of Common Stock
11/29/2006		IsoRay Medical™, Inc. Engages Catalyst Financial Resources
11/15/2006		IsoRay Announces First Quarter 2007 Results and Projected Second Quarter 2007 Sales Revenues
11/01/2006		Silicon Valley Urology Center becomes a national leader in Cesium-131 prostate brachytherapy implants in multiple locations with over 225 cases conducted in Bay Area medical centers
10/17/2006		Chicago Prostate Cancer Center first in world to reach 100 patient implants using Cesium-131 isotope from IsoRay Medical™, Inc.
9/11/2006		IsoRay Announces Appointment of New CFO, Intent to File for a Listing on AMEX, and Increase in Seed Price
9/6/2006		IsoRay Announces Preliminary Fiscal Year 2006 Results and Projected First Quarter 2007 Sales Revenues
8/31/2006		IsoRay Inc. to present at Roth Capital Conference in New York on September 7
8/18/2006		IsoRay Announces First Round of Institutional Financing Led by Microcapital LLC; Raising Over $5 Million
7/26/2006		Cesium-131 seed from IsoRay spotlighted at 48th annual AAPM meeting
7/13/2006		Test at INL completed for IsoRay Medical™
7/10/2006		IsoRay’s Cesium-131 Cancer Therapy Technology Receives R&D100 Award
7/7/2006		IsoRay Announces Withdrawl of NASDAQ Application
7/6/2006		IsoRay begins production testing of Cesium-131 isotope through agreement with Idaho National Laboratory
6/28/2006		IsoRay Medical™ names Eric Knipfer Southeast Area Director
6/22/2006		IsoRay Announces Listing in Standard & Poor's Daily News
6/20/2006		IsoRay Announces Record Seed Orders
6/14/2006		Lori Holmes-Woods joins IsoRay
6/12/2006		IsoRay Announces Warrant Exercise Solicitation and Limited Time Exercise Price Discount
6/9/2006		IsoRay Announces Effectiveness of Registration Statement Relating to 4,637,100 Shares of Common Stock
5/3/2006		IsoRay Medical™, Inc. Receives 2006 Federal Laboratory Consortium Award for Excellence in Technology Transfer
4/26/2006		InterCommunity Cancer Center Introduces Cesium-131 Isotope for Treating Prostate Cancer (First Florida Implant Using Breakthrough Treatment)
4/18/2006		IsoRay names Jonathan R. Hunt corporate controller, announces 44 sites now offering Cesium-131 prostate cancer treatment option
2/15/2006		IsoRay reaches funding, technology, and expansion milestones
2/14/2006		IsoRay tour for future engineering students is subject of Energy Northwest employee publication (Link Opens In Adobe Acrobat Reader)
2/1/2006		Appointment of Dr. Steven Kurtzman as Medical Advisor
1/8/2006		Medical News Today - UK Article: Cesium-131 Brachytherapy, Has Fewer Side Effects